
usd aug pm et
summari compani one largest world-wide provid integr dialysi servic
patient suffer chronic kidney failur
price-to-earnings oper ep
risk assess reflect stabl demand dialysi
servic driven rise senior popul
off-set depend govern payment
payor medicar medicaid
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
lift target
base enterpris valu
ebitda ratio
lower valuat multipl reflect
complet divestitur davita medic
group dmg balanc sheet leverag
much healthier look dmg
busi sold ep vs
beat consensu estim
driven temporari tailwind low-pric
calcimimet chang ep
estim
ep earn
releas mostli in-lin expect
compani alreadi
pre-announc result prior week /kevin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview davita inc lead provid dialysi relat servic
patient suffer chronic kidney failur also known end-stag renal diseas esrd
decemb compani oper provid administr servic network
outpati dialysi center year ago state district columbia serv
total approxim patient dva center specif focus provid outpati
hemodialysi decemb also provid hospit inpati hemodialysi servic
exclud physician servic patient approxim hospit throughout
hemodialysi use artifici kidney call dialyz remov certain toxin fluid salt
patient blood togeth machin control extern blood flow monitor certain vital sign
patient hemodialysi treatment occur outpati dialysi center typic last
approxim three one-half hour usual perform three time per week
market profil esrd state advanc renal impair irrevers requir routin
dialysi treatment kidney transplant sustain life treatment option esrd includ
hemodialysi periton dialysi kidney transplant growth procedur driven
age popul increas incid rate diseas caus kidney failur
diabet hypertens lower mortal rate dialysi patient growth rate minor
popul higher-than-averag incid rate esrd
legal/regulatori issu govern medicar medicaid primari payor
care esrd dialysi patient account dialysi revenu medicar
account major govern revenu esrd payment rate dialysi
establish congress medicar composit rate set center medicar medicaid
servic includ payment dialysi treatment suppli use treatment specifi
laboratori test certain pharmaceut provid paid separ servic
pharmaceut includ erythropoietin epo vitamin analog iron supplement gener
averag cost servic pharmaceut plu small margin base price set medicar
medicar payment rate suffici cover averag cost provid dialysi treatment
cover treatment medicar pay amount set medicar system patient
respons remain case secondari payor cover part
major develop reincarn california bill sb call ab threaten
neg impact previou governor veto bill sb new governor may feel
way
decemb enter agreement sell davita medic group dmg collabor
subsidiari billion cash sale expect close
allow focu core dialysi busi also increas financi
financi trend dva dialysi relat lab servic net revenu per treatment
slightli meanwhil patient care cost per treatment rose
growth dva revenu per treatment pressur patient mix
shift away commerci payer dialysi relat lab servic revenu
commerci percentag decreas addit growth dva
cost outpac net medicar rate increas due inflat labor suppli cost includ
increas mainten cost
dva revenu declin year-over-year primarili due deconsolid
medic group dmg adjust ep grew reflect five-year compound annual growth
rate compound-annual-growth-rate march compani elev level debt given net debt
capit ratio net debt ebitda ratio expect pend divestitur dmg
provid relief debt burden free cash flow million
million
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook health care servic
sub-industri next year posit
base key assumpt
economi current late-stag
econom cycl mean expect
slowdown econom growth mani
firm within sub-industri see
sustain demand servic even
face weaker econom condit
signific advers chang
oper competit environ health
care servic provid sub-industri
recent pressur headlin risk
relat legisl regulatori
propos medicare-for-al amazon
potenti disrupt health sector
elimin rebat believ
headlin unlik evolv
real threat profit health
care servic firm near futur
nonetheless share health care servic
under-perform broader market recent
partial due pressur certain area
laboratori servic provid labcorp
pressur
sustain headwind clinic lab test
manag pbm hurt lower level
drug price inflat increas pressur
third parti payer partial allevi
high util health care servic
firm issu find
suffici qualifi staff think
pressur may account
equiti valuat suggest
potenti upsid
see opportun health care servic
firm address take advantag
recent pressur face
exampl major pbm merg
major insur off-set pressur
notabl acquir aetna
aet ci acquir express script
esrx lab servic provid
opportun acquir smaller lab gain
scale smaller lab like falter
pressur continu signific
back topic headlin risk democrat
took control hous repres
novemb mid-term elect
result chang dynam
washington
republican-domin preced two
appear run medicar
platform would like
lower averag rate health care servic
henc substanti advers impact firm
sub-industri howev think there
almost-zero chanc becom realiti
near futur
anoth headlin risk potenti repeal
afford act instig
judg texa rule
unconstitut case oppon
decis appeal decis
current expect upheld upon
appeal although decis could take
coupl year reach
repeal expect neg impact health
care servic benefit
increas insur coverag past
sever year
year-to-d june health
servic index declin vs
increas
 health servic index
increas vs decreas
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
previou california governor veto bill sb new governor may feel
way /kevin huang cfa
lower twelve-month target base total
enterpris valu ev next-twelve-month ntm ebitda ratio
five-year averag lower ev ntm ebitda ratio
see fewer long-term growth opportun also lower
ep dissip previou regulatori
overhang expect signific catalyst near futur
expect continu spend fend unfavor regulatori propos
think valuat could posit impact strateg
smart capit alloc decis manag especi
divestitur davita medic group dmg busi complet expect
/kevin huang cfa
maintain target base total enterpris
valu ebitda ratio in-lin peer ep
vs lower estim lower ep
ep sale increas
billion total dialysi treatment per-day basi grew
year-over-year sinc earn call two regulatori overhang bill
prop note dissip howev lower
high end oper incom guidanc compani increas
spend relat advocaci chang execut retir polici
anticip increas baselin spend million per year
gener advocaci continu work optum close sale
davita medic group dmg busi end think could
substanti increas share repurchas activ upon close dmg
analyst research note compani news
et cfra maintain hold opinion share davita inc
lift target base enterpris
valu ebitda ratio lower valuat
multipl reflect complet divestitur davita medic group
dmg balanc sheet leverag much healthier look
dmg busi sold ep vs beat consensu
estim driven temporari tailwind low-pric calcimimet
chang ep estim ep
earn releas mostli in-lin expect
compani alreadi pre-announc result prior week /kevin
pm et cfra keep hold opinion share davita inc
share trade midday today announc compani
preliminari result report full earn next thursday
august preliminari result report non-acquir
treatment growth compani lift adjust oper
incom guidanc rang billion rang
billion primarili due non-recurring benefit low-pric
calcimimet drug commonli use dialysi patient
revenu per treatment increas cost per
treatment decreas primarili due lower calcimimet expens higher
labor product also replac share repurchas plan new
billion share repurchas plan expir date /kevin huang cfa
et cfra maintain hold opinion share
share dialysi provid fell today news presid
trump intend reveal plan wednesday juli encourag kidney
transplant at-hom dialysi treatment accord report politico
 depart human servic hh announc new
payment model aim shift treatment away stand-alone clinic
at-hom treatment goal trump plan increas patient
safeti lower cost expect see continu share price volatil
dialysi provid next day /kevin huang cfa
et cfra keep hold opinion share davita inc
lower target base enterpris valu
ebitda ratio ratio equal three-year
averag ep vs lower consensu estim
lower ep ep
adjust oper incom declin yoy million million
line expect weaker-than-expect volum growth off-set
approxim million temporari tailwind calcimimet price
non-acquir volum growth compani long-term
guidanc volum growth hurt growth kidney
transplant increas competit activ highlight
davita medic group dmg sale clear path
obtain ftc approv allevi concern remind effect
june javier rodriguez succeed long-tenur ceo kent thiri /kevin
pm et cfra maintain hold opinion share davita inc
lower target base enterpris
valu ebitda ratio equal dva
averag ep vs lower estim
lower ep initi ep
sale increas billion organ treatment growth
increas year-over-year revenu per treatment decreas
sequenti lower revenu per treatment opinion driven less
favor patient mix expect significantli slow
open treatment center slow growth end-stag renal
diseas industri increas number patient treat
home reincarn california bill sb call ab
threaten neg impact dva revenu
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
